Catalent, Inc., a global company specialising in the development and supply of advanced treatment solutions, has reached a critical milestone in its acquisition by Novo Holdings A/S, a prominent life sciences investment firm. The European Commission (EC) has granted unconditional
Suven Pharmaceuticals has announced the acquisition of a controlling stake in NJ Bio Inc., a Princeton-based CRDMO specialising in Antibody-Drug Conjugates (ADCs) and related emerging modalities. The investment, worth $64.4 million, aligns with Suven’s strategic vision of offering end-to-end solutions
WuXi Biologics has announced significant accomplishments at its state-of-the-art greenfield site in Dundalk, Ireland, marking a key milestone in its global biomanufacturing network. The facility has completed multiple successful 16,000-liter Process Performance Qualification (PPQ) runs, with two completed runs achieving
ProBio, a global contract development and manufacturing organisation (CDMO), has announced a strategic leadership reshuffle effective 1 December 2024. Allen Guo will serve as Chief Executive Officer, Whitney Winters as Senior Vice President of U.S. Business Development, and Michael Vreeland
National Resilience, Inc., a technology-focused biomanufacturing company, has announced William S. Marth as its new President and Chief Executive Officer, effective immediately. Mr. Marth transitions from his previous position as Resilience’s President and Chief Operating Officer, where he oversaw the
Charles River Laboratories has announced the launch of its Charles River Incubator Program (CIP), aimed at helping early-stage biotechnology companies navigate the discovery, development, and manufacturing of advanced therapies. The program, part of the company’s Global Innovation Center of Excellence,
Cambrex, a global CDMO, announced its partnership with Lilly Catalyze360-ExploR&D, the innovation arm of Eli Lilly and Company, to provide development services for Lilly’s biotech collaborators. The collaboration will accelerate early-stage drug development through Cambrex’s expertise in drug substance, drug
NorthStar Medical Radioisotopes and PeptiDream Inc. have entered a strategic collaboration to advance peptide-RI conjugate programs, focusing initially on PDRadiopharma’s CA9 therapeutic asset. PDRadiopharma, a radiopharmaceuticals company in Japan and a wholly owned subsidiary of PeptiDream, will gain access to
Franklin Biolabs, a contract research organisation (CRO) focused on genetic medicines, has announced the appointment of Dr. Vatsala Naageshwaran as its new Chief Executive Officer. Dr. Naageshwaran brings over two decades of experience in the biopharmaceutical industry, having held leadership
Amarna Therapeutics, a biotechnology company focused on transformative gene therapies, has announced a strategic partnership with NorthX Biologics, a company focused on biologics manufacturing. The collaboration will facilitate the development of Nimvec AM510, a gene therapy designed to treat immune-mediated
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
